Fig. 5
CASPER for KRASG12D detection in patients’ pancreatic fine needle aspiration samples. a Fluorescence ratio (left) and fluorescence level over time (right) in the presence of crRNA ASG12D and PCR products from KRASG12D/G12D or KRASWT/WT. b Quantification of the fluorescence ratio at 90 min in the presence of crRNA ASG12D and PCR products from KRASG12D DNA diluted in KRASWT DNA. a-b Results are presented as the mean ± SEM with n = 8 (a) and n = 6 (b) replicates from independent experiments. c Experimental workflow for PDAC patient sample collection, sample processing, and KRASG12D detection with ddPCR and CASPER. d Quantification of the fluorescence ratio of PDAC patient samples at 90 min in the CASPER assay. The values at the top of the bars indicate the mean fluorescence intensity ratios, and the dotted lines indicate a fluorescence ratio of 1. e Quantification of the fluorescence level over time with the CASPER assay for the blank, WT control, and positive patient samples. d-e The red arrows point to the patient 6 results. The results are presented as the mean ± SD with n = 2 replicates from one experiment. *: p < 0.05; **: p < 0.01; ns: not significant